{
    "organizations": [],
    "uuid": "dbf808978d88e257372b5c8d0a99ffda7ed04e9e",
    "author": "",
    "url": "https://www.reuters.com/article/brief-histogenics-corp-qtrly-net-loss-pe/brief-histogenics-corp-qtrly-net-loss-per-common-share-0-26-idUSASC09SD7",
    "ord_in_thread": 0,
    "title": "BRIEF-Histogenics Corp Qtrly Net Loss Per Common Share $0.26",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 35 AM / Updated 11 minutes ago BRIEF-Histogenics Corp Qtrly Net Loss Per Common Share $0.26 Reuters Staff 1 Min Read March 15 (Reuters) - Histogenics Corp: * ORATION ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017 * ‍ NEOCART TOP-LINE PHASE 3 CLINICAL TRIAL DATA AND POTENTIAL BIOLOGICS LICENSE APPLICATION FILING REMAIN ON TRACK FOR Q3 OF 2018​ * ‍AT DECE 31, 2017, CO HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $8.0 MILLION, COMPARED TO $31.9 MILLION AT DECEMBER 31, 2016​ * ‍EXPECTS TOTAL OPERATING EXPENSES OF BETWEEN $29 MILLION AND $31 MILLION FOR YEAR ENDING DECEMBER 31, 2018​ * QTRLY NET LOSS PER COMMON SHARE $0.26 * ‍CURRENT CASH POSITION WILL BE SUFFICIENT TO FUND ITS OPERATIONS INTO Q4 OF 2018​ * Q4 EARNINGS PER SHARE VIEW $-0.27 — THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:",
    "published": "2018-03-15T12:33:00.000+02:00",
    "crawled": "2018-03-15T12:58:45.025+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "corp",
        "qtrly",
        "net",
        "loss",
        "per",
        "common",
        "share",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "histogenics",
        "corp",
        "oration",
        "announces",
        "financial",
        "operating",
        "result",
        "fourth",
        "quarter",
        "year",
        "ended",
        "december",
        "neocart",
        "phase",
        "clinical",
        "trial",
        "data",
        "potential",
        "biologics",
        "license",
        "application",
        "filing",
        "remain",
        "track",
        "q3",
        "dece",
        "co",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "million",
        "compared",
        "million",
        "december",
        "total",
        "operating",
        "expense",
        "million",
        "million",
        "year",
        "ending",
        "december",
        "qtrly",
        "net",
        "loss",
        "per",
        "common",
        "share",
        "cash",
        "position",
        "sufficient",
        "fund",
        "operation",
        "q4",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}